EW

Edwards Lifesciences Corp. 10-Q Summary: Q2 2026

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Edwards Lifesciences Corporation is a global leader in structural heart disease innovation, operating through four geographic segments: United States, Europe, Japan, and Rest of World. The company's product portfolio includes Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical products. Notable corporate actions during the period included the acquisition of Autus Valve Technologies, Inc. in February 2026 and the consolidation of a Variable Interest Entity (VIE) focused on heart failure therapies in May 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13.6% in Q2 and 15.1% YTD compared to the prior year. Growth was driven by TAVR (up 11.3% Q2) and TMTT (up 47.7% Q2) product lines. International sales grew 14.8% in Q2, aided by favorable foreign currency fluctuations.
• Profitability Decline: Despite revenue growth, Net Income attributable to Edwards decreased 27.4% in Q2 and 10.0% YTD. This was primarily due to a significant increase in the effective tax rate and non-operating impairment charges.
• Tax Rate Spike: The effective tax rate for the six months ended June 30, 2026, was 36.4%, compared to 16.1% in the prior year. This increase was driven by a $188.2 million valuation allowance on California R&D tax credits due to new state legislation, reduced benefits from foreign earnings, and global minimum tax (Pillar Two) impacts.
• Impairment Charges: The company recorded a $163.6 million loss on impairment YTD, primarily related to the termination of an option agreement to acquire a VIE and the non-recoverability of another VIE investment.
• Acquisitions: The company recognized a $65.2 million gain on the remeasurement of previously held interest upon the acquisition of Autus and a $19.9 million gain upon consolidating a VIE.

Guidance, Outlook, and Risks

• Outlook: Management expects Pillar Two global minimum tax provisions to result in approximately $50.0 million in additional tax expense for 2026 prior to offsets. The company is assessing the impact of U.S. trade policy and tariffs on its supply chain and demand.
• Capital Allocation: The company repurchased 6.9 million shares for $558.7 million in the first half of 2026, including a $500 million Accelerated Share Repurchase (ASR). Approximately $1.5 billion remains available under the repurchase program.
• Key Risks:
  • Tax Litigation: Significant uncertainty exists regarding IRS audits for tax years 2015-2020. The IRS has issued Notices of Proposed Adjustment (NOPA) proposing substantial increases to taxable income (totaling over $1.5 billion in proposed adjustments for 2018-2020). The company intends to contest these judicially.
  • Intellectual Property: Ongoing litigation regarding patent infringement claims against SAPIEN 3 Ultra and PASCAL products.
  • Regulatory: Dependence on FDA and CE Mark approvals for new product launches and reimbursement levels.

Investor Verification Checklist

• Tax Provision Sustainability: Verify the long-term impact of the California R&D credit valuation allowance and the final resolution of the IRS transfer pricing disputes (2015-2020 tax years).
• Impairment Recurrence: Assess the risk of further impairment charges related to the company's portfolio of VIE investments and acquisition options.
• Product Mix Shift: Confirm the sustainability of the high growth rates in TMTT products (47.7% Q2 growth) and whether this trend will continue to offset slower growth in Surgical products.
• Cash Flow Quality: Review the impact of working capital changes on operating cash flow, noting the $223.4 million outflow for accounts payable and accrued liabilities YTD.
• Acquisition Integration: Monitor the integration progress and milestone achievement for the Autus acquisition and the newly consolidated VIE.